60
Participants
Start Date
May 15, 2023
Primary Completion Date
March 25, 2024
Study Completion Date
April 27, 2024
Bupivacaine
Bupivacaine 0.25%
Bupivacaine + Magnesium
Bupivacaine 0.25% + Magnesium
Bupivacaine + Dexmedetomidine
Bupivacaine 0.25% + Dexmedetomidine
RECRUITING
Walaa Y Elsabeeny, Cairo
National Cancer Institute, Egypt
OTHER